Department of Anesthesia, St. Michael's Hospital, Keenan Research Centre of the Li Ka Shing Knowledge Institute, University of Toronto, Canada.
J Appl Physiol (1985). 2011 Oct;111(4):1125-33. doi: 10.1152/japplphysiol.01340.2010. Epub 2011 Jul 28.
Acute β-blockade with metoprolol has been associated with increased mortality by undefined mechanisms. Since metoprolol is a relatively high affinity blocker of β(2)-adrenoreceptors, we hypothesized that some of the increased mortality associated with its use may be due to its abrogation of β(2)-adrenoreceptor-mediated vasodilation of microvessels in different vascular beds. Cardiac output (CO; pressure volume loops), mean arterial pressure (MAP), relative cerebral blood flow (rCBF; laser Doppler), and microvascular brain tissue Po(2) (G2 oxyphor) were measured in anesthetized mice before and after acute treatment with metoprolol (3 mg/kg iv). The vasodilatory dose responses to β-adrenergic agonists (isoproterenol and clenbuterol), and the myogenic response, were assessed in isolated mesenteric resistance arteries (MRAs; ∼200-μm diameter) and posterior cerebral arteries (PCAs ∼150-μm diameter). Data are presented as means ± SE with statistical significance applied at P < 0.05. Metoprolol treatment did not effect MAP but reduced heart rate and stroke volume, CO, rCBF, and brain microvascular Po(2), while concurrently increasing systemic vascular resistance (P < 0.05 for all). In isolated MRAs, metoprolol did not affect basal artery tone or the myogenic response, but it did cause a dose-dependent impairment of isoproterenol- and clenbuterol-induced vasodilation. In isolated PCAs, metoprolol (50 μM) impaired maximal vasodilation in response to isoproterenol. These data support the hypothesis that acute administration of metoprolol can reduce tissue oxygen delivery by impairing the vasodilatory response to β(2)-adrenergic agonists. This mechanism may contribute to the observed increase in mortality associated with acute administration of metoprolol in perioperative patients.
美托洛尔的急性β阻断作用通过未定义的机制与死亡率增加相关。由于美托洛尔是β(2)-肾上腺素能受体的相对高亲和力阻断剂,我们假设其使用相关的一些死亡率增加可能是由于其阻断了不同血管床中小血管的β(2)-肾上腺素能受体介导的血管舒张。在麻醉小鼠中,在急性给予美托洛尔(3mg/kg iv)前后测量心输出量(CO;压力-容积环)、平均动脉压(MAP)、相对脑血流量(rCBF;激光多普勒)和微血管脑组织 Po(2)(G2 oxyphor)。评估了β-肾上腺素能激动剂(异丙肾上腺素和克仑特罗)的血管舒张剂量反应,以及孤立的肠系膜阻力动脉(MRAs;约 200-μm 直径)和后脑血管(PCAs~150-μm 直径)的肌源性反应。数据以平均值±SE 表示,统计学意义应用于 P<0.05。美托洛尔治疗不影响 MAP,但降低心率和每搏量、CO、rCBF 和脑微血管 Po(2),同时增加全身血管阻力(所有 P<0.05)。在分离的 MRAs 中,美托洛尔不影响基础动脉张力或肌源性反应,但它确实导致异丙肾上腺素和克仑特罗诱导的血管舒张呈剂量依赖性损害。在分离的 PCAs 中,美托洛尔(50μM)损害了对异丙肾上腺素的最大血管舒张反应。这些数据支持以下假设:急性给予美托洛尔可通过损害β(2)-肾上腺素能激动剂的血管舒张反应来降低组织氧输送。这种机制可能与围手术期患者中观察到的急性给予美托洛尔相关死亡率增加有关。